Sign In
Buy OBSV
$0.102
+0 (+0%)
At Close: Jun 21, 2023
Reviewing ObsEva (NASDAQ:OBSV) & ProMetic Life Sciences (OTCMKTS:PFSCF)
01:56am, Friday, 20'th Feb 2026
Insider and Institutional Ownership 17.5% of ObsEva shares are held by institutional investors. Comparatively, 0.1% of ProMetic Life Sciences shares are held by institutional investors. 14.4% of ObsEv
Contrasting ObsEva (NASDAQ:OBSV) & Avenue Therapeutics (NASDAQ:ATXI)
02:04am, Saturday, 10'th Jan 2026
Risk and Volatility Avenue Therapeutics has a beta of -0.51, indicating that its share price is 151% less volatile than the S&P 500. Comparatively, ObsEva has a beta of 0.68, indicating that its share
ObsEva Announces Delisting from SIX Swiss Exchange and Exemption from Certain Obligations Associated with the Maintenance of Listin
01:00am, Wednesday, 03'rd Apr 2024
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – April 3, 2024 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing and commercializing novel
ObsEva Announces Update on Board of Directors
02:00am, Tuesday, 19'th Mar 2024
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – March 18, 2024 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing and commercializing novel
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – 28 February 2024 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for
Geneva Court Grants Temporary Moratorium to ObsEva
01:00am, Wednesday, 31'st Jan 2024
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – 31 January 2024 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for w
ObsEva Announces Application for a Moratorium to Facilitate Pivotal Deals
01:00am, Thursday, 30'th Nov 2023
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – November 30, 2023 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies fo
Organon Returns Ebopiprant to XOMA
05:00pm, Friday, 27'th Oct 2023
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – October 27, 2023 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies
ObsEva Files half Year 2023 Financial Statements
01:00am, Wednesday, 27'th Sep 2023
ObsEva Files half Year 202 3 Financial Statements
ObsEva Recovers Full Worldwide Rights on Nolasiban
01:00am, Thursday, 13'th Jul 2023
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – Ju ly 13 , 202 3 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies f
What Do Penny Stocks Offer Over Blue Chips?
06:00am, Thursday, 09'th Mar 2023
Why penny stocks might be a better choice for some investors than blue chips The post What Do Penny Stocks Offer Over Blue Chips? appeared first on Penny Stocks to Buy, Picks, News and Information | P
The Most Important Penny Stocks Trading Indicators
06:00am, Monday, 06'th Mar 2023
These indicators can help you to make money with penny stocks The post The Most Important Penny Stocks Trading Indicators appeared first on Penny Stocks to Buy, Picks, News and Information | PennySt
Penny Stocks Trading: How News Plays a Role
11:00am, Sunday, 05'th Mar 2023
Use these tips for making money with penny stocks in 2023 The post Penny Stocks Trading: How News Plays a Role appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Why Is ObsEva (OBSV) Stock Up 93% Today?
08:11am, Friday, 03'rd Mar 2023
ObsEva (NASDAQ: OBSV ) stock is taking off on Friday as investors react to insider buying at the clinical-stage biopharmaceutical company. Ernest Loumaye, a member of the Board of Directors at ObsEva,
Why Novavax Shares Are Trading Lower By Around 28%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
06:16pm, Wednesday, 01'st Mar 2023 Benzinga
Gainers
Reata Pharmaceuticals Inc (NASDAQ: RETA) shares jumped 171.5% to $84.67 after the company reported the FDA approval of SKYCLARYS for patients with Friedreich's Ataxia.
OncoSec Medical Incorpo
